



Prevalence and factors associated with diabetes mellitus among tuberculosis patients: a nationwide cohort

To the Editor:

The association between diabetes mellitus (DM) and tuberculosis (TB) has been a matter of study worldwide, since it is assumed that DM triples the risk of TB [1]. Recent studies have found discrepant prevalence of DM among TB patients, ranging from 5.3% in Denmark [2] to 44% in India [3]. There is an urgent need to control both epidemics in order to achieve the World Health Organization (WHO) TB elimination goal [4]. To reach this goal, an integrated approach between TB elimination strategies and control of noncommunicable diseases that perpetuate the risk for TB is fundamental [5].

Portugal has an intermediate incidence rate of TB and an estimated prevalence of DM of 7.4% (estimated underdiagnosed prevalence of 5.7%) [6]. There are no official recommendations to actively screen for DM in TB patients (there is only a provisional recommendation from the WHO Collaborative Framework for Care and Control of Tuberculosis and Diabetes [7]). A previous systematic review estimated that if TB patients were screened for DM, the DM prevalence would range widely, from 1.9% to 35% [8]. This study aims to assess DM prevalence among the Portuguese TB population and to identify which factors are associated with it. This is a Portuguese nationwide retrospective cohort study of a 6-year period (2008–2013).

Data were collected from the national TB database, SVIG-TB (Sistema de Vigilância da TB em Portugal (System for Surveillance of TB in Portugal)) [9]. All patients diagnosed with TB in Portugal are mandatorily recorded through this registry. We included all patients with newly diagnosed pleural-pulmonary TB who finished treatment between January 2008 and December 2013. Exclusion criteria were age <18 years, previous TB diagnosis, isolated extrapulmonary TB, multidrug- or extensively drug-resistant TB and unknown outcome (abandonment/emigration).

The following definitions were used. TB diagnosis: positive culture or both smear and nucleic acid amplification test positivity in a pleural or respiratory specimen; DM diagnosis: self-reported by the patient and/or based on clinical data; TB compliance: $\geq 80\%$ of prescribed treatment; unsuccessful treatment: death, lack of microbiological conversion and/or incomplete treatment (<80% of prescribed treatment); drug consumer: regular consumer of illicit drugs. All the comorbidities analysed (including DM itself) were reported to the Portuguese surveillance system, SVIG-TB [9].

For the statistical analysis, categorical variables were described by absolute (relative) frequencies, while continuous variables were described by the median (interquartile range (IQR)). For all variables, a comparative analysis between patients with and without DM was performed: Chi-squared or Fisher test (as adequate) for the study of independence among categorical variables, and the Mann–Whitney test for the assessment of statistically significant differences between two independent continuous variables.

DM prevalence (6.0%) and the number of possible predictors hindered a straightforward application of a multiple logistic regression model. Initially, random oversampling of the DM class, until the two classes had exactly the same number of observations, was performed and for each oversample, a classification tree was created. As all trees exhibited essentially the same structure, the tree considered was the one obtained from the repetition of the DM class until the achievement of exact balance. This procedure reduced the number of predictors to a smaller subset. Then a logistic regression model was performed, considering the variables assigned with a predictive importance greater than zero. The imbalance was then dealt with as follows: 1) oversampling of the DM class using full-size random selection with replacement; 2) logistic regression with the obtained dataset and saving of the estimated coefficients; 3) repetition of the procedure 1000 times. A regression coefficient was considered to be statistically significant if its values did not include zero, disregarding the adequate lower and upper percentiles.

Statistical analyses were carried out using the R language and software environment for statistical computation, version 2.12.1 (R Foundation for Statistical Computing, Vienna, Austria). The significance level was set at 0.05.

Ethical approval was not required since data were already anonymised according to national data protection rules.

TABLE 1 Factors associated with diabetes mellitus in the Portuguese population with tuberculosis from 2008 to 2013

	Patients n	Diabetes mellitus		Bivariate analysis		Multiple analysis			
		No n (%)	Yes n (%)	OR (95% CI)	p-value	OR (95% CI)	Estimate [#]	Lower bound [#]	Upper bound [#]
Sex	11317								
Male	7894	7410 [69.7]	484 [71.1]	1.070 [0.902–1.269]	0.440	1.044 [0.999–1.088]	0.044	–0.001	0.084
Female	3423	3226 [30.3]	197 [28.9]	Reference					
Foreign origin	11317								
Yes	1787	1709 [16.1]	78 [11.5]	0.676 [0.531–0.860]	0.001				
No	9530	8927 [83.9]	603 [88.5]	Reference					
Alcohol dependence	10661								
Yes	1650	1557 [15.5]	93 [14.5]	0.921 [0.734–1.154]	0.474				
No	9011	8462 [84.5]	549 [85.5]	Reference					
i.v. drug user	10680								
Yes	746	734 [7.3]	12 [1.9]	0.241 [0.135–0.429]	<0.001	0.603 [0.494–0.729]	–0.505	–0.706	–0.316
No	9934	9303 [92.7]	631 [98.1]	Reference					
Other drug user	10647								
Yes	880	862 [8.6]	18 [2.8]	0.306 [0.191–0.491]	<0.001	0.643 [0.557–0.742]	–0.442	–0.586	–0.299
No	9767	9143 [91.4]	624 [97.2]	Reference					
Reclusion	10854								
Yes	201	192 [1.9]	9 [1.4]	0.723 [0.369–1.417]	0.342				
No	10653	10004 [98.1]	649 [98.6]	Reference					
Homelessness	10851								
Yes	181	174 [1.7]	7 [1.1]	0.620 [0.290–1.326]	0.213				
No	10670	10020 [98.3]	650 [98.9]	Reference					
Communitarian shelter	10805								
Yes	329	307 [3.0]	22 [3.3]	1.107 [0.713–1.719]	0.651				
No	10476	9839 [97.0]	637 [96.7]	Reference					
HIV	11317								
Yes	1123	1097 [10.3]	26 [3.8]	0.345 [0.232–0.513]	<0.001	0.497 [0.432–0.564]	–0.700	–0.840	–0.573
No	10194	9539 [89.7]	655 [96.2]	Reference					
Haematological malignancies	11317								
Yes	33	30 [0.3]	3 [0.4]	1.564 [0.476–5.139]	0.448				
No	11284	10606 [99.7]	678 [99.6]	Reference					
Lung cancer	11317								
Yes	117	109 [1.0]	8 [1.2]	1.148 [0.558–2.364]	0.708				
No	11200	10527 [99.0]	673 [98.8]	Reference					
Other cancers	11317								
Yes	298	262 [2.5]	36 [5.3]	2.210 [1.546–3.159]	<0.001				
No	11019	10374 [97.5]	645 [94.7]	Reference					
COPD	11317								
Yes	286	259 [2.4]	27 [4.0]	1.654 [1.104–2.478]	0.014				
No	11031	10377 [97.6]	654 [96.0]	Reference					
Liver disease	11317								
Yes	425	393 [3.7]	32 [4.7]	1.285 [0.889–1.859]	0.182				
No	10892	10243 [96.3]	649 [95.3]	Reference					
Renal failure[¶]	11317								
Yes	109	92 [0.9]	17 [2.5]	2.934 [1.739–4.952]	<0.001				
No	11208	10636 [99.1]	664 [97.5]	Reference					
Silicosis	11317								
Yes	138	131 [1.2]	7 [1.0]	0.833 [0.388–1.789]	0.639				
No	11179	10505 [98.8]	674 [99.0]	Reference					

Continued

TABLE 1 Continued

	Patients n	Diabetes mellitus		Bivariate analysis		Multiple analysis			
		No n (%)	Yes n (%)	OR (95% CI)	p-value	OR (95% CI)	Estimate [#]	Lower bound [#]	Upper bound [#]
Sarcoidosis	11317				1.000				
Yes	12	12 (0.1)	0 (0)						
No	11305	10624 (99.9)	681 (100)						
Other diffuse lung disease	11317				0.411				
Yes	28	28 (0.3)	0 (0)						
No	11289	10608 (99.7)	681 (100)						
Inflammatory joint disease	11317				0.022				
Yes	58	50 (0.5)	8 (1.2)	2.517 (1.188–5.330)					
No	11259	10586 (99.5)	673 (98.8)	Reference					
Abnormal radiograph	10685				0.137				
Yes	10319	9671 (96.5)	648 (97.6)	1.466 (0.883–2.434)					
No	366	350 (3.5)	16 (2.4)	Reference					
Cavitation	10685				0.226				
Yes	5132	4798 (47.9)	334 (50.3)	1.102 (0.942–1.289)					
No	5553	5223 (52.1)	330 (49.7)	Reference					
Fatal adverse drug reaction	9031				0.099				
Yes	297	273 (3.2)	24 (4.5)	1.430 (0.933–2.191)					
No	8734	8228 (96.8)	506 (95.5)	Reference					
Isoniazid resistance	7348				0.632				
Yes	450	419 (6.1)	31 (6.6)	1.097 (0.752–1.599)					
No	6898	6462 (93.9)	436 (93.4)	Reference					
Rifampicin resistance	7349				0.697				
Yes	93	88 (1.3)	5 (1.1)	0.836 (0.338–2.067)					
No	7256	6794 (98.7)	462 (98.9)	Reference					
Ethambutol resistance	7342				0.607				
Yes	65	60 (0.9)	5 (1.1)	1.229 (0.491–3.076)					
No	7277	6815 (99.1)	462 (98.9)	Reference					
Pyrazinamide resistance	5681				0.707				
Yes	102	96 (1.8)	6 (1.6)	0.853 (0.371–1.958)					
No	5579	5198 (98.2)	381 (98.4)	Reference					
Streptomycin resistance	7260				0.793				
Yes	713	666 (9.8)	47 (10.2)	1.043 (0.763–1.425)					
No	6547	9132 (90.2)	415 (89.8)	Reference					
Treatment success	10403				<0.001				
Yes	9655	9107 (93.2)	548 (86.3)	0.457 (0.360–0.581)					
No	748	661 (6.8)	87 (13.7)	Reference					
Mortality	10403				<0.001	1.098 (1.031–1.172)	0.094	0.031	0.159
Yes	746	659 (6.7)	87 (13.7)	2.194 (1.727–2.789)					
No	9657	9109 (93.3)	548 (86.3)	Reference					
Age years		43.0 (33.0–56.0) [†]	60.0 (50.0–72.0) [†]	1.044 (1.039–1.048)	<0.001	1.047 (1.046–1.049)	0.046	0.045	0.047
Time from symptoms to diagnosis days		60.0 (36.0–102.0) [†]	66.0 (39.0–112.0) [†]	1.000 (1.000–1.001)	0.209				

COPD: chronic obstructive pulmonary disease. [#]: results from the logistic regression methodology; the “Estimate” column corresponds to the mean of all estimates obtained within the procedure, while the “Lower bound” and “Upper bound” columns correspond to the 0.025 and 0.975 quantiles, respectively; if 0 is not within the given interval, then the variable is statistically significant for a 0.05 significance level. [†]: haemodialysis. ^{*}: median (interquartile range).

During the studied period, 11 317 TB patients were recorded (median (IQR) age 44 (33–58) years; 69.8% males). The global prevalence of DM in the present cohort was 6.0% and stable during the studied period. There was a male predominance in patients both with and without DM (71.1% and 69.7%, respectively). Patients with DM were significantly older ($p < 0.001$), with half being aged > 60 years (table 1). Moreover, they had a significantly higher rate of malignancies other than haematological or lung cancer (OR 2.210, 95% CI 1.546–3.159), of chronic obstructive pulmonary disease (OR 1.654, 95% CI 1.104–2.478), of renal failure under haemodialysis treatment (OR 2.934, 95% CI 1.739–4.952) and of inflammatory joint disease (OR 2.517, 95% CI 1.188–5.330). Patients with DM also had a significantly lower rate of HIV infection (OR 0.345, 95% CI 0.232–0.513), consumption of intravenous (OR 0.241, 95% CI 0.135–0.429) or other drugs (OR 0.306, 95% CI 0.191–0.491) and were less often foreign born (OR 0.676, 95% CI 0.531–0.860). No differences were identified in TB radiological manifestation or in the delay from symptoms to TB diagnosis. Patients with DM presented a significantly lower rate of treatment success (OR 0.457, 95% CI 0.360–0.581) and a higher rate of death during treatment (OR 2.194, 95% CI 1.727–2.789).

In the multiple analysis, the odds for DM among TB patients increased by 4.7% per year of age (OR 1.047, 95% CI 1.046–1.049) but decreased by $\sim 50\%$ in HIV-positive patients (OR 0.497, 95% CI 0.432–0.564), 39.7% in *i.v.* drug consumers (OR 0.603, 95% CI 0.494–0.729) and 35.7% in drug consumers other than *i.v.* (OR 0.643, 95% CI 0.557–0.742). Moreover, the odds for DM among those who died were 9.8% higher (OR 1.098, 95% CI 1.031–1.172).

The factors associated with DM among TB patients identified in this study were older age, no drug consumption and no HIV infection. Death occurred more often among DM patients. No other clinical, radiological or sociodemographic factor predicted DM.

DM, particularly type 2 DM, is strongly related to older age in developed countries where most patients are above the retirement age, whereas in developing countries those most frequently affected are aged 35–64 years [10]. In developed countries most TB patients tend to be younger than the retirement age. This might explain why DM prevalence among TB patients is significantly lower in countries like Portugal (6.0%), Spain (5.9%) [11] and Denmark (5.3%) [2], in comparison with developing countries where, however, increasing age is also related to the presence of DM in TB [3].

Being HIV positive was related to a lower DM prevalence among TB patients even when controlled for age. Similar results were found in other studies [11]. In the same way, being a consumer of *i.v.* or other drugs was associated with a lower risk of DM even when controlled for age and HIV status. There are no known protective factors for DM among those who are HIV positive or drug consumers. More studies are needed to clarify why these TB patients present a lower risk for DM.

This study showed that death during TB treatment was 9.8% higher in patients with DM. These results are in line with some other studies [12–15] but in conflict with a recently published article [11]. Advanced age, comorbidities and drug interactions are reasonable factors that may be related to death. Nevertheless, it is still unknown if there is any pathological mechanism between TB and DM that explains the poorer outcomes.

In previous studies, foreign origin [16], changes in chest radiography [11, 13, 14, 17], adverse drug reactions [11] or sex [18] were significantly associated with DM among TB patients. In the present study, none of these factors were related to DM comorbidity.

The present study has limitations, especially due to its retrospective nature: 1) DM could not be actively confirmed; 2) death causes could not be determined. Nevertheless, because of the nationwide nature of our study, the size of our sample and the constantly improving TB registry, we are confident that these results clarify the role of DM among Portuguese TB patients. To our knowledge, a systematic nationwide survey concerning DM among TB patients has never previously been conducted, which reinforces the importance of this study's results to the comprehension of the TB–DM relationship.

To conclude, in this nationwide Portuguese TB cohort, DM was associated with older patients, lack of HIV infection and lack of drug consumption. Further studies should analyse the causes of mortality among this group in order to define new strategies to improve outcomes.



@ERSpublications

In a Portuguese TB cohort, diabetes mellitus was associated with older age and no HIV infection or drug consumption <http://ow.ly/10EoN1>

João Cordeiro da Costa^{1,2}, Olena Oliveira², Luís Baía³, Rita Gaio^{3,4}, Margarida Correia-Neves^{5,6} and Raquel Duarte^{1,2,7}
¹Pulmonology Dept, Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Vila Nova de Gaia, Portugal. ²EPI Unit, Public Health Institute, University of Porto, Porto, Portugal. ³Mathematics Dept, Faculty of Sciences, University of Porto, Porto, Portugal. ⁴Centre of Mathematics, University of Porto, Porto, Portugal. ⁵Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. ⁶ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal. ⁷Clinical Epidemiology, Predictive Medicine and Public Health Dept, Medical School, University of Porto, Porto, Portugal.

Correspondence: João Cordeiro da Costa, Serviço de Pneumologia do Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Rua Conceição Fernandes, 4434-502 Vila Nova de Gaia, Portugal. E-mail: joaocordeirodacosta@hotmail.com

Received: Feb 03 2016 | Accepted after revision: March 31 2016

Support statement: This work was supported by the Portuguese Foundation for Science and Technology (FCT), grant number PTDC/DTP-PIC/0747/2012. Funding information for this article has been deposited with FundRef.

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

References

- 1 Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. *PLoS Med* 2008; 5: e152.
- 2 Leegaard A, Riis A, Kornum JB, *et al.* Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. *Diabetes Care* 2011; 34: 2530–2535.
- 3 Balakrishnan S, Vijayan S, Nair S, *et al.* High diabetes prevalence among tuberculosis cases in Kerala, India. *PLoS One* 2012; 7: e46502.
- 4 Lönnroth K, Migliori GB, Abubakar I, *et al.* Towards tuberculosis elimination: an action framework for low-incidence countries. *Eur Respir J* 2015; 45: 928–952.
- 5 Creswell J, Raviglione M, Ottmani S, *et al.* Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. *Eur Respir J* 2011; 37: 1269–1282.
- 6 Observatório Nacional da Diabetes, Sociedade Portuguesa de Diabetologia. Diabetes: Factos e Números – O Ano de 2014 – Relatório Anual do Observatório Nacional da Diabetes [Diabetes: Facts and Figures – The Year 2014 – Annual Report of the National Diabetes Centre]. Lisbon, Observatório Nacional da Diabetes, 2015. http://spd.pt/images/ond_2015.pdf
- 7 World Health Organization, The International Union Against Tuberculosis and Lung Disease. Collaborative Framework for Care and Control of Tuberculosis and Diabetes. WHO/HTM/TB/2011.15. Geneva, World Health Organization, 2011. http://apps.who.int/iris/bitstream/10665/44698/1/9789241502252_eng.pdf
- 8 Jeon CY, Harries AD, Baker MA, *et al.* Bi-directional screening for tuberculosis and diabetes: a systematic review. *Trop Med Int Health* 2010; 15: 1300–1314.
- 9 Direção-Geral da Saúde. Sistema SVIG-TB [SVIG-TB system]. www.dgs.pt/paginas-de-sistema/saude-de-a-a-z/tuberculose1/sistema-svig-tb.aspx Date last updated: March 11, 2014. Date last accessed: March 3, 2016.
- 10 World Health Organization, International Diabetes Federation. Diabetes Action Now. Geneva, World Health Organization, 2004. www.who.int/diabetes/actionnow/en/DANbooklet.pdf
- 11 Moreno-Martínez A, Casals M, Orcau À, *et al.* Factors associated with diabetes mellitus among adults with tuberculosis in a large European city, 2000–2013. *Int J Tuberc Lung Dis* 2015; 19: 1507–1512.
- 12 Baker MA, Harries AD, Jeon CY, *et al.* The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med* 2011; 9: 81.
- 13 Reed GW, Choi H, Lee SY, *et al.* Impact of diabetes and smoking on mortality in tuberculosis. *PLoS One* 2013; 8: e58044.
- 14 Magee MJ, Foote M, Maggio DM, *et al.* Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009–2012. *Ann Epidemiol* 2014; 24: 369–375.
- 15 Dooley KE, Tang T, Golub JE, *et al.* Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. *Am J Trop Med Hyg* 2009; 80: 634–639.
- 16 Demlow SE, Oh P, Barry PM. Increased risk of tuberculosis among foreign-born persons with diabetes in California, 2010–2012. *BMC Public Health* 2015; 15: 263.
- 17 Jiménez-Corona ME, Cruz-Hervert LP, García-García L, *et al.* Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. *Thorax* 2013; 68: 214–220.
- 18 Mi F, Tan S, Liang L, *et al.* Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou, China. *Trop Med Int Health* 2013; 18: 1379–1385.

Eur Respir J 2016; In press | DOI: 10.1183/13993003.00254-2016 | Copyright ©ERS 2016